AegirBio AB

Equities

AEGIR

SE0014401121

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 11:16:15 2024-04-29 am EDT			5-day change	1st Jan Change
0.495 ^SEK	-4.62%		-1.20%	-57.69%

Apr. 19	AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract	MT
Apr. 09	AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas	MT

AegirBio AB Reports Earnings Results for the First Quarter Ended March 31, 2023

May 31, 2023 at 05:49 pm EDT

AegirBio AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 0.056 million compared to SEK 1.39 million a year ago. Net loss was SEK 16.76 million compared to SEK 14.25 million a year ago.

Latest news about AegirBio AB

AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract	Apr. 19	MT
AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas	Apr. 09	MT
AegirBio Chairman to Resign	Apr. 09	MT
AegirBio AB Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman	Apr. 09	CI
AegirBio AB Enters into Conditional Agreement on a SEK 45 Million Loan Facility with Atlas Special Opportunities, LLC	Apr. 09	CI
AegirBio AB Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
AegirBio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
AegirBio AB Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board	Feb. 27	CI
AegirBio AB Appoints Adam S. Cheifetz as Scientific Advisory Board	Jan. 24	CI
AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 24	CI
AegirBio Receives Portion of National Institutes of Health Award	Nov. 01	MT
AegirBio Shifts Business Focus to Diagnostics Initiative in US	Nov. 01	MT
Aegirbio AB Receives Phase 1 Award from the National Institutes of Health Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing	Nov. 01	CI
Aegirbio Focuses on RadX Project, Will Not Uphold Ce-Markings for the Magniareader TDM Tests	Nov. 01	CI
Sweden's AegirBio Names New COO	23-10-09	MT
AegirBio Announces Management Changes	23-10-09	CI
Aegirbio AB Receives $1.2 Million NIH Award	23-10-06	CI
AegirBio AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
AegirBio AB Receives National Institutes of Health Programmatic Approval for an Accessibility Project	23-07-17	CI
Aegirbio Signs Agreement with Salofa for the Veterinary Market and Receives A First Order Worth Approximately SEK 2 Million	23-07-07	CI
AegirBio COO to Depart in December	23-06-19	MT
AegirBio AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Aegirbio AB Announces CEO Changes	23-05-30	CI
AegirBio to Pay SEK1.3 Billion Fine Instead of Delisting; Shares Skyrocket 127%	23-03-14	MT
Aegirbio AB Announces Sales of Viraspec Covid-19 Tests Are Being Resumed	23-02-28	CI

Chart AegirBio AB

Duration

Period

More charts

Company Profile

AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-16 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AEGIRBIO AB	-57.69%	1.46M
THERMO FISHER SCIENTIFIC	+8.69%	219B
DANAHER CORPORATION	+6.69%	183B
INTUITIVE SURGICAL, INC.	+10.90%	133B
BOSTON SCIENTIFIC CORPORATION	+25.41%	108B
SIEMENS HEALTHINEERS AG	+0.27%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+12.72%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	48.2B
AGILENT TECHNOLOGIES, INC.	+0.40%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+15.03%	39.35B

Other Advanced Medical Equipment & Technology